Testosterone MDL Judge: No Duty Under Florida Law To Provide Different Warning

Mealey's (November 13, 2020, 12:20 PM EST) -- CHICAGO — The Illinois federal judge overseeing the testosterone replacement therapy multidistrict litigation on Nov. 4 denied summary judgment in a case headed for trial, saying that under Florida law, a prescription drug manufacturer has a duty to provide warnings “in a manner apart from the FDA-approved package insert” (In re Testosterone Replacement Therapy Products Liability Litigation [Douglas L. Davis v. Actavis, Inc., et al., No. 19-3775], MDL Docket No. 2545, No. 14-1748, N.D. Ill., Eastern Div., 2020 U.S. Dist. LEXIS 206128)....